Treatment of NB cells with proteasome inhibitor MG132 resulted in increased MYCN protein levels that remained relatively high even under CCNB1IP1 knockdown, suggesting that CCNB1IP1 protects MYCN protein from ubiquitin proteasome‐mediated degradation (Figure 5G). The gene discussed is CCNB1IP1; the disease is neuroblastoma.